世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Fibromyalgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global fibromyalgia treatment market is on a steady growth trajectory, with market valuation projected to rise from USD 1.5 billion in 2025 to USD 2.5 billion by 2032, advancing at a CAGR of 7.... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global fibromyalgia treatment market is on a steady growth trajectory, with market valuation projected to rise from USD 1.5 billion in 2025 to USD 2.5 billion by 2032, advancing at a CAGR of 7.57% during the forecast period. Fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain, fatigue, cognitive disturbances, and sleep disorders, continues to pose diagnostic and treatment challenges worldwide. As the medical community deepens its understanding of central sensitization and associated comorbidities, the demand for effective and personalized treatment solutions is surging.Market Insights Despite the absence of a definitive cure, the fibromyalgia treatment Analysis is evolving, with pharmaceutical and non-pharmaceutical interventions offering partial relief from symptoms. Pharmaceutical treatments such as anticonvulsants, antidepressants, and analgesics continue to dominate the market. Simultaneously, non-pharmaceutical approaches-like cognitive behavioral therapy (CBT), physical therapy, and alternative therapies-are increasingly being integrated into multimodal treatment plans. The burden of fibromyalgia is significant, affecting approximately 2–4% of the global population, with higher prevalence in women. The chronic and idiopathic nature of the syndrome often results in reduced quality of life and high healthcare utilization, prompting sustained demand for both approved and off-label therapeutic approaches. Key Market Drivers The primary factors propelling market growth include increasing research and development investments aimed at identifying novel therapeutic targets, expanding clinical trials for emerging drug candidates, and growing awareness of fibromyalgia among healthcare providers and patients. The exploration of combination therapy and repositioning of existing drugs for off-label use has further widened treatment possibilities. Moreover, enhanced understanding of the pathophysiology-particularly the role of central and peripheral nervous system mechanisms in pain perception-has driven innovation in the development of targeted therapies. Companies are also investing in patient-tailored treatments that focus on managing coexisting conditions such as depression, chronic fatigue syndrome, irritable bowel syndrome, and anxiety. Business Opportunity One of the most promising opportunities lies in the development of combination therapies and re-evaluation of existing medications for fibromyalgia management. Although current therapies only moderately relieve symptoms in a subset of patients, there is scope for improvement through interdisciplinary research and collaborative clinical programs. The rise of telehealth and digital therapeutics also offers new pathways to deliver cognitive behavioral therapy and personalized care remotely, especially in underserved areas. Furthermore, as regulatory bodies across different regions streamline drug approval processes and prioritize research funding, pharmaceutical companies have greater incentives to develop targeted fibromyalgia therapies. Regional Analysis North America is expected to maintain its dominant position in the fibromyalgia treatment market, driven by the high prevalence of fibromyalgia, increased healthcare spending, and strong presence of leading pharmaceutical manufacturers. The availability of generic versions of key drugs and active pipelines from companies such as Aptinyx Inc. and Prismic Pharmaceuticals continue to support market momentum in the region. Europe is anticipated to witness moderate growth due to growing awareness and rising healthcare expenditure, particularly in Germany where short-term use of drugs like pregabalin and duloxetine is recommended in national guidelines despite lack of formal approvals. Meanwhile, the Asia Pacific region is poised for the fastest growth rate, attributed to the increasing burden of rheumatic diseases, expanding elderly population, and greater efforts to improve disease awareness. In China, where fibromyalgia commonly coexists with rheumatoid arthritis and other musculoskeletal conditions, the market is expanding rapidly. Key Players Prominent players operating in the fibromyalgia treatment market include: • Pfizer, Inc. • Eli Lilly and Company • AbbVie, Inc. • Teva Pharmaceutical Industries Ltd. • Sanofi • Johnson & Johnson Services, Inc. • GlaxoSmithKline plc • TONIX Pharmaceuticals Holdings Corp • Virios Therapeutics, Inc. • Aptinyx Inc. • FSD Pharma • Bayer AG These companies are focusing on pipeline development, clinical trials, and strategic partnerships to strengthen their market presence. Market Challenges The growth of the market may be restrained by several factors, including the limited number of approved drugs, variable treatment efficacy, high cost of branded therapies, and lack of reimbursement for newly introduced medications. Additionally, inconsistent adherence to prescribed treatment regimens and the chronic nature of fibromyalgia further complicate disease management and treatment outcomes. Market Segmentation By Drug Class: • Antidepressants (Venlafaxine, Duloxetine HCl, Milnacipran HCl, Others) • Anticonvulsants (Pregabalin, Gabapentin, Others) • Muscle Relaxants • Analgesics By Distribution Channel: • Hospital Pharmacies • Drug Stores • Retail Pharmacies • Online Pharmacies By Region: • North America • Latin America • Europe • South Asia • East Asia • Oceania • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Fibromyalgia Treatment Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Fibromyalgia Treatment Market Outlook, 2019-2032 3.1. Global Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032 3.1.1. Key Highlights 3.1.1.1. Antidepressants 3.1.1.1.1. Venlafaxine 3.1.1.1.2. Duloxetine HCl 3.1.1.1.3. Milnacipran HCl 3.1.1.1.4. Others 3.1.1.2. Anticonvulsants 3.1.1.2.1. Pregabalin 3.1.1.2.2. Gabapentin 3.1.1.2.3. Others 3.1.1.3. Muscle Relaxants 3.1.1.4. Analgesics 3.2. Global Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 3.2.1. Key Highlights 3.2.1.1. Hospitals Pharmacies 3.2.1.2. Drug Stores 3.2.1.3. Retail Pharmacies 3.2.1.4. Online Pharmacies 3.3. Global Fibromyalgia Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032 3.3.1. Key Highlights 3.3.1.1. North America 3.3.1.2. Europe 3.3.1.3. Asia Pacific 3.3.1.4. Latin America 3.3.1.5. Middle East & Africa 4. North America Fibromyalgia Treatment Market Outlook, 2019-2032 4.1. North America Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032 4.1.1. Key Highlights 4.1.1.1. Antidepressants 4.1.1.1.1. Venlafaxine 4.1.1.1.2. Duloxetine HCl 4.1.1.1.3. Milnacipran HCl 4.1.1.1.4. Others 4.1.1.2. Anticonvulsants 4.1.1.2.1. Pregabalin 4.1.1.2.2. Gabapentin 4.1.1.2.3. Others 4.1.1.3. Muscle Relaxants 4.1.1.4. Analgesics 4.2. North America Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 4.2.1. Key Highlights 4.2.1.1. Hospitals Pharmacies 4.2.1.2. Drug Stores 4.2.1.3. Retail Pharmacies 4.2.1.4. Online Pharmacies 4.2.2. BPS Analysis/Market Attractiveness Analysis 4.3. North America Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032 4.3.1. Key Highlights 4.3.1.1. U.S. Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 4.3.1.2. U.S. Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 4.3.1.3. Canada Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 4.3.1.4. Canada Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 4.3.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Fibromyalgia Treatment Market Outlook, 2019-2032 5.1. Europe Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Antidepressants 5.1.1.1.1. Venlafaxine 5.1.1.1.2. Duloxetine HCl 5.1.1.1.3. Milnacipran HCl 5.1.1.1.4. Others 5.1.1.2. Anticonvulsants 5.1.1.2.1. Pregabalin 5.1.1.2.2. Gabapentin 5.1.1.2.3. Others 5.1.1.3. Muscle Relaxants 5.1.1.4. Analgesics 5.2. Europe Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Hospitals Pharmacies 5.2.1.2. Drug Stores 5.2.1.3. Retail Pharmacies 5.2.1.4. Online Pharmacies 5.2.2. BPS Analysis/Market Attractiveness Analysis 5.3. Europe Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Germany Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 5.3.1.2. Germany Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.3. U.K. Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 5.3.1.4. U.K. Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.5. France Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 5.3.1.6. France Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.7. Italy Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 5.3.1.8. Italy Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.9. Turkey Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 5.3.1.10. Turkey Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.11. Russia Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 5.3.1.12. Russia Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 5.3.1.13. Rest of Europe Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 5.3.1.14. Rest of Europe Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 5.3.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Fibromyalgia Treatment Market Outlook, 2019-2032 6.1. Asia Pacific Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Antidepressants 6.1.1.1.1. Venlafaxine 6.1.1.1.2. Duloxetine HCl 6.1.1.1.3. Milnacipran HCl 6.1.1.1.4. Others 6.1.1.2. Anticonvulsants 6.1.1.2.1. Pregabalin 6.1.1.2.2. Gabapentin 6.1.1.2.3. Others 6.1.1.3. Muscle Relaxants 6.1.1.4. Analgesics 6.2. Asia Pacific Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Hospitals Pharmacies 6.2.1.2. Drug Stores 6.2.1.3. Retail Pharmacies 6.2.1.4. Online Pharmacies 6.2.2. Others BPS Analysis/Market Attractiveness Analysis 6.3. Asia Pacific Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032 6.3.1. Key Highlights 6.3.1.1. China Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 6.3.1.2. China Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.3. Japan Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 6.3.1.4. Japan Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.5. South Korea Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 6.3.1.6. South Korea Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.7. India Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 6.3.1.8. India Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.9. Southeast Asia Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 6.3.1.10. Southeast Asia Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 6.3.1.11. Rest of Asia Pacific Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 6.3.1.12. Rest of Asia Pacific Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 6.3.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Fibromyalgia Treatment Market Outlook, 2019-2032 7.1. Latin America Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Antidepressants 7.1.1.1.1. Venlafaxine 7.1.1.1.2. Duloxetine HCl 7.1.1.1.3. Milnacipran HCl 7.1.1.1.4. Others 7.1.1.2. Anticonvulsants 7.1.1.2.1. Pregabalin 7.1.1.2.2. Gabapentin 7.1.1.2.3. Others 7.1.1.3. Muscle Relaxants 7.1.1.4. Analgesics 7.2. Latin America Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 7.2.1. Key Highlights 7.2.1.1. Hospitals Pharmacies 7.2.1.2. Drug Stores 7.2.1.3. Retail Pharmacies 7.2.1.4. Online Pharmacies 7.2.2. BPS Analysis/Market Attractiveness Analysis 7.3. Latin America Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Brazil Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 7.3.1.2. Brazil Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 7.3.1.3. Mexico Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 7.3.1.4. Mexico Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 7.3.1.5. Argentina Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 7.3.1.6. Argentina Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 7.3.1.7. Rest of Latin America Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 7.3.1.8. Rest of Latin America Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 7.3.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Fibromyalgia Treatment Market Outlook, 2019-2032 8.1. Middle East & Africa Fibromyalgia Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Antidepressants 8.1.1.1.1. Venlafaxine 8.1.1.1.2. Duloxetine HCl 8.1.1.1.3. Milnacipran HCl 8.1.1.1.4. Others 8.1.1.2. Anticonvulsants 8.1.1.2.1. Pregabalin 8.1.1.2.2. Gabapentin 8.1.1.2.3. Others 8.1.1.3. Muscle Relaxants 8.1.1.4. Analgesics 8.2. Middle East & Africa Fibromyalgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Hospitals Pharmacies 8.2.1.2. Drug Stores 8.2.1.3. Retail Pharmacies 8.2.1.4. Online Pharmacies 8.2.2. BPS Analysis/Market Attractiveness Analysis 8.3. Middle East & Africa Fibromyalgia Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032 8.3.1. Key Highlights 8.3.1.1. GCC Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 8.3.1.2. GCC Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.3. South Africa Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 8.3.1.4. South Africa Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.5. Egypt Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 8.3.1.6. Egypt Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.7. Nigeria Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 8.3.1.8. Nigeria Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 8.3.1.9. Rest of Middle East & Africa Fibromyalgia Treatment Market by Drug Class, Value (US$ Bn), 2019-2032 8.3.1.10. Rest of Middle East & Africa Fibromyalgia Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032 8.3.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Manufacturer vs by Distribution Channel Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Pfizer, Inc 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Development 9.4.2. Eli Lilly and Company 9.4.2.1. Company Overview 9.4.2.2. Product Portfolio 9.4.2.3. Financial Overview 9.4.2.4. Business Strategies and Development 9.4.3. AbbVie, Inc. 9.4.3.1. Company Overview 9.4.3.2. Product Portfolio 9.4.3.3. Financial Overview 9.4.3.4. Business Strategies and Development 9.4.4. Teva Pharmaceutical Industries Ltd. 9.4.4.1. Company Overview 9.4.4.2. Product Portfolio 9.4.4.3. Financial Overview 9.4.4.4. Business Strategies and Development 9.4.5. Johnson & Johnson Services, Inc 9.4.5.1. Company Overview 9.4.5.2. Product Portfolio 9.4.5.3. Financial Overview 9.4.5.4. Business Strategies and Development 9.4.6. Sanofi 9.4.6.1. Company Overview 9.4.6.2. Product Portfolio 9.4.6.3. Financial Overview 9.4.6.4. Business Strategies and Development 9.4.7. GlaxoSmithKline plc. 9.4.7.1. Company Overview 9.4.7.2. Product Portfolio 9.4.7.3. Financial Overview 9.4.7.4. Business Strategies and Development 9.4.8. Bayer AG 9.4.8.1. Company Overview 9.4.8.2. Product Portfolio 9.4.8.3. Financial Overview 9.4.8.4. Business Strategies and Development 9.4.9. TONIX Pharmaceuticals Holdings Corp 9.4.9.1. Company Overview 9.4.9.2. Product Portfolio 9.4.9.3. Financial Overview 9.4.9.4. Business Strategies and Development 9.4.10. Virios Therapeutics, Inc. 9.4.10.1. Company Overview 9.4.10.2. Product Portfolio 9.4.10.3. Financial Overview 9.4.10.4. Business Strategies and Development 9.4.11. Aptinyx Inc. 9.4.11.1. Company Overview 9.4.11.2. Product Portfolio 9.4.11.3. Financial Overview 9.4.11.4. Business Strategies and Development 9.4.12. FSD Pharma 9.4.12.1. Company Overview 9.4.12.2. Product Portfolio 9.4.12.3. Financial Overview 9.4.12.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
